WO2024015941 - DINUCLEOTIDES AND THEIR USE IN TREATING CANCER
National phase entry:
Publication Number
WO/2024/015941
Publication Date
18.01.2024
International Application No.
PCT/US2023/070177
International Filing Date
13.07.2023
Title **
[English]
DINUCLEOTIDES AND THEIR USE IN TREATING CANCER
[French]
DINUCLÉOTIDES ET LEUR UTILISATION DANS LE TRAITEMENT DU CANCER
Applicants **
MAIA BIOTECHNOLOGY, INC.
Inventors
GRYAZNOV, Sergei
SHAY, Jerry
Priority Data
63/388,688
13.07.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address | * |
| Type of Assignment | * |
| Applicant's Legal Status | * |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under | * |
| Patent Delivery | * |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 5851 | |
| EPO | Filing, Examination, Granting | 116324 | |
| Japan | Filing, Examination, Granting | 5091 | |
| South Korea | Filing, Examination, Granting | 9656 | |
| USA | Filing, Examination, Granting | 42360 |
Total:
179,282
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Disclosed herein are dinucleotide compounds that target telomers in cancer cells and methods for using the dinucleotide compounds to treat cancers alone or before administration with checkpoint inhibitors.[French]
L'invention concerne des composés dinucléotidiques qui ciblent des télomères dans des cellules cancéreuses et des procédés d'utilisation des composés dinucléotidiques pour traiter des cancers seuls ou avant l'administration avec des inhibiteurs de points de contrôle.